Drug product development for highly potent APIs (HPAPIs) can be challenging. Complications with the interface between operations in drug substance and drug product handling can result in increased program complexity and cost. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine. This year’s conference will focus on case studies related to development, rapid scaling, validation and commercial production of HPAPI drug substance, as well as integrated containment requirements for particle engineering and drug product.

In a constantly evolving innovative time, companies continue to wrestle for deriving more value from their “business and corporate strategies”. The significance of a business strategy relies on it being a viable way to build up business desires, creating a competitive advantage and additionally increment shareholder value to something beyond the aggregate of its physical resources. MarketsandMarkets Chief Strategy Officer Forum invites leading strategy executives from Fortune 2000 companies who are making the future.

What’s your role in Business Strategies? Are you struggling to stay ahead in competition? How do you adhere to the gap between strategic intelligence and decision making?

MarketsandMarkets is hosting an inaugural Microbiome - Advanced Therapeutics and Sequencing Congress on September 19 - 20 2019 in Philadelphia, USA gathering pharma, biotech, academicians and investors to exchange views and observe most ingenious microbiome research and technologies.

Over the two days, the congress will address:

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.

Focused on the impact of two technologies on manufacturers, our conference is going one step further by addressing a series of application-based illustrations and discussions to map the future possibility of trends in the manufacturing world.

Improving clinical translation in neuroscience research has always been a major challenge until now. There are many research collaborations happening in the neuroscience space today for neurodegenerative disorders research. The conference will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims to bring in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries.

While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.

Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon. The conference will address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

In a constantly evolving innovative time, companies continue to wrestle for deriving more value from their “business and corporate strategies”. The significance of a business strategy relies on it being a viable way to build up business desires, creating a competitive advantage and additionally increment shareholder value to something beyond the aggregate of its physical resources. MarketsandMarkets Chief Strategy Officer Forum invites leading strategy executives from Fortune 2000 companies who are making the future.

With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year’s congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.

District cooling is one of the nine strategic pillars in Dubai Supreme Council of Energy’s Demand Side Management strategy, towards achieving 30% power savings in the emirate by 2030. The major steps for enhancing district cooling adoption includes planning and educating the top players in real estate firms on the advantages and guiding on the knowledge of technical know-how.

This conclave aims to provide a platform to experts from Government bodies, regulatory authorities, real estate firms, special economic zones, hotel owners and operators, free zones from UAE and rest of GCC and solution providers.